Viking Therapeutics posts bigger-than-expected Q3 loss as costs rise
VKTX•Viking Therapeutics reported a third-quarter net loss of $183.19 million, or $1.55 per share, missing analyst estimates of $126.73 million and $1.07 per share. The company ended the quarter with $960 million in cash and expects results from several trial milestones in 2027 and 2028.
1. Quarterly results
Viking Therapeutics reported a third-quarter net loss of $183.19 million, or $1.55 per share, compared with analyst estimates of $126.73 million and $1.07 per share. Operating expenses were $187.11 million, driven by higher research and development and administrative costs.
2. Cash and trial outlook
The company ended the quarter with $960 million in cash after upsized public offerings. Viking expects Phase 3 VANQUISH obesity trials to be completed in 2027, results from VANQUISH extension studies in 2028, and results from Part 2 of its VK2735 maintenance dosing study in 2027.
